ArticlePloS one2017
Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review.Parasitology research · 2018Pooled it
- Host-directed therapeutic strategies against apicomplexan parasites: targeting purinergic P2 receptors.Purinergic signalling · 2026Review
- Potential Molecular Targets of the Broad-Range Antimicrobial Peptide Tyrothricin in the Apicomplexan ParasiteBiomedicines · 2026Article
- Identification of a mouse-virulent recombinant type I/III Toxoplasma gondii strain in liver cytology of an immunosuppressed cat infected with FeLV-C subgroup.Veterinary research communications · 2025Article
- Review of Toxoplasmosis: What We Still Need to Do.Veterinary sciences · 2025Review
- Protective Efficacy Induced by Virus-like Particles Expressing Dense Granule Protein 5 ofVaccines · 2025Article
- Host-Parasite Interactions inInternational journal of molecular sciences · 2024Article
- Transient Adaptation ofInternational journal of molecular sciences · 2024Article
- N-acetylglucosamine supplementation fails to bypass the critical acetylation of glucosamine-6-phosphate required for Toxoplasma gondii replication and invasion.PLoS pathogens · 2024Article
- Gestational toxoplasmosis treatment changes the child's prognosis: A cohort study in southern Brazil.PLoS neglected tropical diseases · 2023Article
- The apicoplast is important for the viability and persistence ofProceedings of the National Academy of Sciences of the United States of America · 2023Article
- The In Vitro Anti-Parasitic Activities of Emodin towardPharmaceuticals (Basel, Switzerland) · 2023Article
- A High-Throughput Amenable Dual Luciferase System for MeasuringAnalytical chemistry · 2023Article
- Advances towards the completeFaculty reviews · 2023Review
- In vitro maturation of Toxoplasma gondii bradyzoites in human myotubes and their metabolomic characterization.Nature communications · 2022Article
- Drug repositioning: antiprotozoal activity of terfenadine against Entamoeba histolytica trophozoites.Parasitology research · 2022Article
- Unifying Virulence Evaluation inFrontiers in cellular and infection microbiology · 2022Review
- Impact of Plant-Based Foods and Nutraceuticals onFrontiers in nutrition · 2022Review
- Systematic Analysis of Clemastine, a Candidate Apicomplexan Parasite-Selective Tubulin-Targeting Agent.International journal of molecular sciences · 2021Article
- Toxoplasmosis: Current and Emerging Parasite Druggable Targets.Microorganisms · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Drug treatment for toxoplasmosis is problematic, because current drugs cannot eradicate latent infection with Toxoplasma gondii and can cause bone marrow toxicity. Because latent infection remains after treatment, relapse of infection is a problem in both infections in immunocompromised patients and in congenitally infected patients. To identify lead compounds for novel drugs against Toxoplasma gondii, we screened a chemical compound library for anti-Toxoplasma activity, host cell cytotoxicity, and effect on bradyzoites. Of 878 compounds screened, 83 demonstrated >90% parasite growth inhibition. After excluding compounds that affected host cell viability, we further characterized two compounds, tanshinone IIA and hydroxyzine, which had IC50 values for parasite growth of 2.5 μM and 1.0 μM, respectively, and had no effect on host cell viability at 25 μM. Both tanshinone IIA and hydroxyzine inhibited parasite replication after invasion and both reduced the number of in vitro-induced bradyzoites, whereas, pyrimethamine, the current therapy, had no effect on bradyzoites. Both tanshinone IIA and hydroxyzine are potent lead compounds for further medicinal chemistry. The method presented for evaluating compounds for bradyzoite efficacy represents a new approach to the development of anti-Toxoplasma drugs to eliminate latency and treat acute infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.